{
    "clinical_study": {
        "@rank": "55342", 
        "arm_group": [
            {
                "arm_group_label": "BG00012 Part 1", 
                "arm_group_type": "Experimental", 
                "description": "BG00012 120 mg delivered to varying locations of the GI tract"
            }, 
            {
                "arm_group_label": "BG00012 Part 2", 
                "arm_group_type": "Experimental", 
                "description": "BG00012 240 mg delivered to varying locations of the GI tract"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the pharmacokinetics (PK) profile of\n      monomethyl fumarate (MMF) following delivery of BG00012 120 mg (Part 1) and BG00012 240 mg\n      (Part 2) to varying regions within the GI tract in healthy volunteers.  The secondary\n      objective of this study is to evaluate the safety and tolerability profile following the\n      delivery of BG00012 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within\n      the GI tract in healthy volunteers."
        }, 
        "brief_title": "BG00012 Regional Absorption Study", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or non-pregnant, non-lactating healthy females.\n\n          -  Body mass index (BMI) of 18 through 35 kg/m2.\n\n          -  Subjects of childbearing potential (including males) must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             90 days after their last dose of study treatment\n\n        Exclusion Criteria:\n\n          -  History of or positive test result at Screening for human immunodeficiency virus\n             (HIV), hepatitis C virus (HCV) antibody, or hepatitis B virus (defined as positive\n             for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).\n\n          -  Serious infection (e.g., pneumonia, septicemia) within the 3 months prior to first\n             dose.\n\n          -  Vaccinations within 4 weeks prior to first dose.\n\n          -  History of drug or alcohol abuse (as defined by the Investigator) within the previous\n             2 years, or regular alcohol consumption in males >21 units per week and females >14\n             units per week (1 unit = \u00bd pint of beer, 25 mL of 40% spirit or a 125 mL glass of\n             wine).\n\n          -  History of clinically significant gastrointestinal (GI) disease as determined by the\n             Investigator (including Crohn's Disease, Ulcerative Colitis, confirmed diagnosis of\n             active Irritable Bowel Syndrome).\n\n          -  History of any clinically significant cardiac, endocrinologic, hematologic, hepatic,\n             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,\n             and renal, or other major disease, as determined by the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924832", 
            "org_study_id": "109HV111", 
            "secondary_id": "EUDRA CT NO: 2013-002048-96"
        }, 
        "intervention": [
            {
                "arm_group_label": "BG00012 Part 1", 
                "description": "120 mg tablet, single dose", 
                "intervention_name": "BG00012 (dimethyl fumarate [DMF])", 
                "intervention_type": "Drug", 
                "other_name": "DMF"
            }, 
            {
                "arm_group_label": "BG00012 Part 2", 
                "description": "240 mg tablet, single dose", 
                "intervention_name": "BG00012 (dimethyl fumarate [DMF])", 
                "intervention_type": "Drug", 
                "other_name": "DMF"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dimethyl fumarate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NJ116JS"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BG00012 (Dimethyl Fumarate) When Delivered to Different Regions of the Gastrointestinal Tract in Healthy Subjects", 
        "overall_contact": {
            "email": "Neurologyclinicaltrials@biogenidec.com", 
            "last_name": "Medical Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The maximum observed concentration: Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to to week 9"
            }, 
            {
                "measure": "The time to reach maximum observed concentration: Tmax", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "The area under the plasma concentration versus time curve from time zero to 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "The area under the plasma concentration versus time curve from time zero to time t (the last sampling time with quantifiable monomethyl fumarate [MMF])", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "The area under the plasma concentration versus time curve from time zero to infinity", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "The apparent elimination half-life", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "The time prior to the first quantifiable monomethyl fumarate (MMF) plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) ratio of test regimens compared with reference for Part 1", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) ratio of test regimens compared with reference for Part 2", 
                "safety_issue": "No", 
                "time_frame": "Up to week 9"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924832"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The number of subjects that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to week 9"
        }, 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}